SoftBank Vision Fund, a subsidiary of Japan’s SoftBank Group Co, has led the $400-million Series C funding round in US-based biotechnology firm Relay Therapeutics, according to a statement Thursday. The financing round was also participated by Foresite Capital, Perceptive Advisors, and Tavistock Group. Existing GV, Casdin Capital, BVF Partners, EcoR1 Capital, Alexandria Venture Investments, and an affiliate of D.E. Shaw Research also backed the round. Proceeds from this financing are anticipated to be used to accelerate the implementation of Relay Therapeutics’ long-term strategy. Relay said the fresh funds will support the expansion of the company’s discovery efforts, advance existing programs into the clinic and bolster its broad platform and diverse team. Read full story at AsiaPEVC.com

Share.